Kira Wampler
DoximityAbout Kira Wampler
Kira Wampler, 52 as of July 1, 2025, has served as an independent Class I director of Doximity (DOCS) since March 2020; she is Venture Chair at Redesign Health (since February 2020), was CEO of Art.com (Nov 2016–Mar 2019, led sale to Walmart), and previously CMO at Lyft (Dec 2014–Nov 2016) and Trulia (Nov 2013–Nov 2014). She holds a B.S. from Georgetown University’s School of Foreign Service (History and Diplomacy) and an MBA from Duke University’s Fuqua School of Business .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Redesign Health Inc. | Venture Chair | Feb 2020–present | Healthcare innovation; investor/operating leadership |
| Art.com Inc. | Chief Executive Officer | Nov 2016–Mar 2019 (led sale to Walmart) | Led strategic sale; operating turnaround |
| Lyft, Inc. | Chief Marketing Officer | Dec 2014–Nov 2016 | Scaled marketing at ride-sharing platform |
| Trulia, Inc. | Chief Marketing Officer | Nov 2013–Nov 2014 | Marketing leadership in real estate tech |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Candid Care Co. (private) | Director | Sep 2019–Jan 2023 | Oral health startup |
| Personal Capital Corporation (private) | Director | Mar 2019–Aug 2020 | Digital wealth management |
| Healthline Media, Inc. (private) | Director | Mar 2019–Aug 2019 | Health media |
| Current public company boards | None disclosed | — | DOCS proxy lists private boards; no current public boards for Wampler |
Board Governance
- Board class and term: Class I director nominated for re‑election to a term through the 2028 annual meeting; plurality voting standard applies .
- Independence: The board affirmatively determined Wampler is independent under NYSE rules .
- Committee assignments: Member, Compensation Committee (Kevin Spain, Chair); Chair, Nominating & Governance Committee; both committees comprised of independent directors and operate under written charters .
- Meeting cadence and attendance: FY2025 board held 5 meetings; Compensation Committee held 4 meetings and acted by unanimous written consent 3 times; Nominating & Governance held 3 meetings and acted by unanimous written consent once; each director attended at least 75% of board and applicable committee meetings .
- Board leadership structure: CEO serves as Board Chair (no separate lead independent director disclosed), which can concentrate authority; governance mitigants include fully independent committees and annual self-evaluations per guidelines .
- Hedging/pledging policy: Company prohibits directors from hedging, short selling, trading derivatives, holding shares in margin accounts, or pledging shares; a one‑time pledging exception was granted to the CEO in Nov 2023 and terminated May 2025 (no exceptions disclosed for directors) .
Fixed Compensation
| Component | FY2025 Policy Amount ($) | FY2025 Actual Cash Earned ($) |
|---|---|---|
| Board annual retainer | 35,000 | 49,625 (aggregate cash fees) |
| Compensation Committee member retainer | 7,500 | Included in cash total |
| Nominating & Governance Committee chair retainer | 9,000 | Included in cash total |
| Lead director / non‑executive chair retainers | 15,000 / 25,000 (if applicable) | Not applicable to Wampler |
Notes
- Cash fees are paid quarterly in advance; actual earned can reflect proration or timing. Wampler’s FY2025 total cash fees were $49,625 .
Performance Compensation
| Equity Grant Type | Policy Value ($) | Vesting | FY2025 Grant Date Fair Value ($) |
|---|---|---|---|
| Annual RSU Grant | 200,000 (value based on trailing 30‑day closing price avg) | Vests in full on earlier of first anniversary or next annual meeting; accelerates on “Sale Event” | 233,348 (Wampler’s FY2025 stock awards) |
| Initial RSU Grant (upon joining board) | 400,000 | 3‑year annual tranches; accelerates on “Sale Event” | Not applicable in FY2025 |
- No performance‑based equity metrics (e.g., PSUs) are used for non‑employee director grants; RSUs are service‑based under the 2021 Plan limits ($750,000 ongoing annual cap; $1,000,000 initial cap including cash) .
Other Directorships & Interlocks
| Area | Detail |
|---|---|
| Compensation Committee interlocks | Compensation Committee comprised of independent directors (Spain, Yang, Wampler); no compensation committee interlocks disclosed; Spain’s cash fees paid to Emergence Capital per employer policy . |
| Related party transactions | No Wampler‑specific related party transactions disclosed; board reviews/approves any related party transactions via Audit Committee policy . |
Expertise & Qualifications
- Multi‑industry operating leadership (CEO at Art.com; senior marketing at Lyft/Trulia) with technology and consumer growth expertise; healthcare venture leadership via Redesign Health; board experience across private companies .
- Academic credentials: Georgetown University School of Foreign Service (B.S., History and Diplomacy); Duke Fuqua MBA .
Equity Ownership
| As of Date | Class A Shares | Class B Shares | Ownership % | Notes |
|---|---|---|---|---|
| June 11, 2025 (beneficial ownership table) | 10,258 | 474,700 | <1% of total ownership and voting power | Class B carries 10 votes per share; convertible 1:1 into Class A . |
| March 31, 2025 (outstanding awards snapshot) | RSUs outstanding: 6,360 | Options outstanding: 485,700 | — | Market value of RSUs determined at $58.03 close for aggregate director table; individual director RSU count disclosed . |
Alignment/Restrictions
- Director ownership is primarily via stock options and RSUs; hedging/pledging prohibited for directors under insider trading policy (no exceptions disclosed for Wampler) .
Governance Assessment
- Strengths: Independent director and Chair of Nominating & Governance, signaling active role in board composition, evaluations, and governance guidelines; meets attendance expectations (≥75%); compensation mix is mostly equity ($233,348 stock awards vs $49,625 cash) supporting alignment; robust insider trading and anti‑hedging/pledging policy for directors .
- Risks/Red Flags: CEO also serves as Board Chair (no disclosed lead independent director), potentially concentrating authority; ongoing securities class action and derivative litigation naming certain directors indicates elevated oversight risk for the board overall (defendants intend to defend vigorously) .
- Conflicts: No Wampler‑specific related party transactions disclosed; independence affirmed after review of relationships; continued monitoring prudent given venture role in healthcare (Redesign Health) though no transactions with DOCS are disclosed .
- Compensation Committee Practices: Committee uses an independent consultant (Aon), assessed for independence/no conflicts; annual risk assessment of compensation programs; independent membership and chartered responsibilities indicate sound governance processes .
Director Compensation (FY2025)
| Name | Fees Earned or Paid in Cash ($) | Stock Awards ($) | Total ($) |
|---|---|---|---|
| Kira Wampler | 49,625 | 233,348 | 282,973 |
Committee Assignments
| Committee | Role | FY2025 Meetings / Actions |
|---|---|---|
| Nominating & Governance | Chair | 3 meetings; 1 unanimous written consent |
| Compensation | Member | 4 meetings; 3 unanimous written consents |
Attendance & Engagement
| Body | FY2025 Meetings | Attendance |
|---|---|---|
| Board of Directors | 5 | Each director attended ≥75% of board and committee meetings served |
Policies Affecting Alignment and Risk
- Hedging/Pledging: Prohibited for directors; CEO’s one‑time loan collateral exception ended May 2025 .
- Governance Guidelines: Independent majority; annual board and committee self‑evaluations; authority to retain independent advisors .
- Say‑on‑Pay Signal: 98.6% support in 2024, indicating shareholder confidence in compensation design (for NEOs) .
Overall, Wampler’s independence, committee leadership, and equity‑heavy compensation support board effectiveness and alignment; primary governance watchpoint is the combined CEO/Chair structure and pending shareholder litigation, both of which warrant continued monitoring for impact on investor confidence .